Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence

NACompletedINTERVENTIONAL
Enrollment

28,153

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
HIV Infection
Interventions
DRUG

Immediate ARV treatment initiation with TDF/FTC/EFV

"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."

OTHER

South African recommendation guided ARV (TDF/FTC/EFV) initiation

"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."

Trial Locations (1)

3937

Hlabisa Hospital, Hlabisa

All Listed Sponsors
collaborator

Africa Centre For Health and Population Studies

OTHER

collaborator

University of KwaZulu

OTHER

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT01509508 - Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence | Biotech Hunter | Biotech Hunter